糖原合酶激酶3β抑制剂TDZD-8对急性肝衰竭小鼠肝组织炎症的保护作用研究*

doi:10.3969/j.issn.1672-5069.2023.03.006

Abstract

Abstract: Objective The aim of this study was to investigate the protective effect of glycogen synthase kinase 3β (GSK3β) inhibitor TDZD-8 on liver injuries in mice with D-Gal/LPS-induced acute liver failure(ALF). Methods Twenty-four male mice were randomly divided into control, model and TDZD-8-intervened group, with eight in each. The model of ALF was established by intraperitoneal injection of D-Gal/LPS. Serum free DNA (cf-DNA) was detected by fluorescent dye, and liver homogenate tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) were assayed by ELISA. The hepatic expression of L-18, IL-1β, UNC-51-like kinase 1 (ULK1), Beclin 1 and P62 were detected by Western blotting. Results Serum ALT, AST and total bilirubin levels in model group were (3460.8±105.2)U/L, (2710.4±84.3)U/L and (93.8±1.1)μmol/L, all significantly higher than [(28.1±4.2)U/L,(25.78±2.5)U/L and (3.4±0.4)μmol/L, respectively, P<0.05] in the control, while they all greatly decreased in TDZD-8-intervened group [(370.1±7.1)U/L, (277.3±20.3)U/L and (35.1±0.8)μmol/L, respectively, P<0.05]; the liver homogenate TNF-α, IL-1β and serum cf-DNA levels in the model were (3004.6±239.2)pg/mL, (469.6±56.7)pg/mL and (772.2±192.2) ng/mL, while they all greatly decreased in TDZD-8-intervened group [(2353.3±284.7)pg/mL, (339.2±48.7)pg/mL and (180.0±15.4)ng/mL, respectively, P<0.05]; the hepatic expression of IL-18 and IL-1β in the model intensified greatly as compared to in the control (P<0.05), while they both became weaker in TDZD-8-intervened group (P<0.05); the relative hepatic expression of ULK1 and Beclin1 obviously decreased(P<0.05), and the hepatic expression of P62 protein increased greatly(P<0.05)compared to in the control, while the ULK1 and Beclin1 expression greatly intensified, and the P62 expression became weaker (P<0.05) in TDZD-8-intervened mice. Conclusion The inhibition of GSK3β activity in a mouse model of acute liver failure could protect the liver injuries, which might be related to the up-regulation of autophagy and the inhibition of inflammatory cytokine release.

Key words: Acute liver failure, Glycogen synthase kinase3β, Autophagy, Cytokines

Zhang Danmei , Shi Chunxia , Chen Qian, et al.. Protective effect of glycogen synthase kinase 3β inhibitor TDZD-8 on liver injuries in mice with D-Gal/LPS-induced acute liver failure[J]. Journal of Practical Hepatology, 2023, 26(3): 324-327.

References

[1] 汪娅,罗婷婷,李璨,等.曲美他嗪对急性肝衰竭小鼠肝组织NOX2和NOX4表达的影响. 实用肝脏病杂志, 2021, 24(6): 799-802.
[2] Dong V, Nanchal R, Karvellas C J. Pathophysiology of acute liver failure. Nutr Clin Pract, 2020, 35(1): 24-29.
[3] Deretlc V. Autophagy in inflammation, infection, and immunometabolism. Immunity, 2021, 54(3): 437-453.
[4] Emma M R, Augello G, Cusimano A, et al. GSK-3 in liver diseases: friend or foe? Biochim Biophys Acta Mol Cell Res, 2020, 1867(9): 118743.
[5] Huang B, Liu J, Meng T, et al. Polydatin prevents lipopolysaccharide (LPS)-induced Parkinson's disease via regulation of the AKT/GSK3β-Nrf2/NF-κB signaling axis. Front Immunol, 2018, 92:527.
[6] Pan H Y, Valapala M. Regulation of autophagy by the glycogen synthase kinase-3 (GSK-3) signaling pathway. Int J Mol Sci, 2022, 23(3): 385-389.
[7] Liu Q, Kong Y, Guo X, et al. GSK-3β inhibitor TDZD-8 prevents reduction of aquaporin-1 expression via activating autophagy under renal ischemia reperfusion injury. Faseb J, 2021, 35(8): e21809.
[8] Zou W, Ye D, Liu S, et al. GSK-3β inhibitors attenuate the PM2.5-induced inflammatory response in bronchial epithelial cells . Int J Chron Obstruct Pulmon Dis, 2021, 16(28):45-56.
[9] Zheng H, Yang Z, Xin Z, et al. Glycogen synthase kinase-3beta: a promising candidate in the fight against fibrosis. Theranostics, 2020, 10(25): 11737-11753.
[10] Lyu H, Liu Q, Wen Z, et al. Xanthohumol ameliorates lipopolysaccharide (LPS)-induced acute lung injury via induction of AMPK/GSK3β-Nrf2 signal axis. Redox Biol, 2017, 12(3):11-24.
[11] Luo R, Su L Y, Li G, et al. Activation of PPARA-mediated autophagy reduces Alzheimer disease-like pathology and cognitive decline in a murine model. Autophagy, 2020, 16(1): 52-69.
[12] Deng J, Wang X, Zhou Q, et al. Inhibition of glycogen synthase kinase 3β alleviates chronic renal allograft dysfunction in rats. Transplantation, 2021, 105(4): 757-767.
[13] Zhang L, Zhao Y, Fan L, et al. Tectorigenin protects against experimental fulminant hepatic failure by regulating the TLR4/mitogen-activated protein kinase and TLR4/nuclear factor-κB pathways and autophagy. Phytother Res, 2019, 33(4): 1055-1064.
[14] Yang Y, Wang H, Kouadir M, et al. Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell Death Dis, 2019, 10(2): 128.
[15] Sanders Y Y. New clue: prediction from cell-free DNA. J Clin Med, 2020, 9(7):422-426.
[16] Zhao J, Wang H, Huang Y, et al. Lupus nephritis: glycogen synthase kinase 3β promotion of renal damage through activation of the NLRP3 inflammasome in lupus-prone mice. Arthritis Rheumatol, 2015, 67(4): 1036-1044.
[17] Zhao R, Xiao H, Jin T, et al. Naringenin promotes cell autophagy to improve high-fat-diet-induced atherosclerosis in ApoE-/- mice. Braz J Med Biol Res, 2021, 54(4): e9764.
[18] Kim J, Kundu M, Viollet B, et al. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol, 2011, 13(2): 132-141.
[19] Di Malta C, Cinque L, Settembre C. Transcriptional regulation of autophagy: mechanisms and diseases. Front Cell Dev Biol, 2019, 7(1):14.
[20] Ren F, Zhang L, Zhang X, et al. Inhibition of glycogen synthase kinase 3β promotes autophagy to protect mice from acute liver failure mediated by peroxisome proliferator-activated receptor α. Cell Death Dis, 2016, 7(3): e2151.

Protective effect of glycogen synthase kinase 3β inhibitor TDZD-8 on liver injuries in mice with D-Gal/LPS-induced acute liver failure

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Ling Jiahui, Ni Meixin, Han Lili, et al.. Serum cytokine changes in patients with autoimmune hepatitis receiving magnesium isoglycyrrhizinate treatment [J]. Journal of Practical Hepatology, 2023, 26(2): 214-217.
[2]	Cheng Xiaoyan, Zhao Aiming, Li Haidan, et al.. Distribution of pathogens and serum Th1/Th2 cytokine changes in patients with hepatitis B virus related acute-on-chronic liver failure and nosocomial infections [J]. Journal of Practical Hepatology, 2023, 26(2): 246-249.
[3]	Luo Suyan, Li Tingting, Wang Yaqi,et al.. Diagnostic performance of peripheral blood Treg/Th17 cells and their related cytokines in predicting significant liver fibrosis in patients with primary biliary cholangitis [J]. Journal of Practical Hepatology, 2022, 25(5): 673-676.
[4]	Wang Xiaoyan, Zhong Xueyu, Wu Chunyan. Impact of saxagliptin on AMPK/mTOR-TFEB autophagy signaling pathway in rats with non-alcoholic fatty liver disease and concomitant type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2022, 25(4): 476-479.
[5]	Liu Haitao, Zhang Leiming, Li Jingwei. Clinical and pathological features in patients with drug-induced liver injury [J]. Journal of Practical Hepatology, 2022, 25(4): 508-511.
[6]	He Yajuan, Wang Fei, Yao Naijuan, et al. Hepatitis B whole x gene promotes inflammation reaction of hepatic stellate cells and triggers hepatocyte apoptosis in vitro [J]. Journal of Practical Hepatology, 2022, 25(3): 323-326.
[7]	Wang Ya, Luo Tingting, Li Can, et al. Effects of trimetazidine on the expression of NOX2 and NOX4 in liver tissues of mice with acute liver failure [J]. Journal of Practical Hepatology, 2021, 24(6): 799-802.
[8]	Huang Liou, Wu Chunrong, Xu Dan, et al. Efficacy of continuous renal replacement therapy without heparinization in patients with liver cirrhosis complicated by hepatic encephalopathy [J]. Journal of Practical Hepatology, 2021, 24(6): 875-878.
[9]	Tang Shuangyi, Wang Xibin, Qiu Yue, et al. Effects of sirolimus on hepatic TLR4 expression and autophagy in mice with partial hepatic warm ischemia-reperfusion injury [J]. Journal of Practical Hepatology, 2021, 24(5): 669-672.
[10]	Zhang Jia, Jin Mingyuan, Du Yanyun, et al. Serum cytokine changes in patients with nonalcoholic fatty liver diseases and helicobacter pylori infection after clearance therapy [J]. Journal of Practical Hepatology, 2021, 24(4): 500-503.
[11]	Dang Ling, Jia Ai, Wang Fang. Prognosis of patients with subacute liver failure by serumlipopolysaccharide binding protein and sCD163 levels [J]. Journal of Practical Hepatology, 2021, 24(3): 447-448.
[12]	Li Zhao, Huang Zansong , Li Fan. Application of fenofibrate and bicyclol combination in treatment of patients with non-alcoholic fatty liver diseases and changes of hepatic PPARγ₂ [J]. Journal of Practical Hepatology, 2021, 24(1): 59-62.
[13]	Huang Heming, Liu Yanjun, Fu Rong, et al. Protective effect of bromo- and extra-terminal domain inhibitor (+), JQ1 on LPS / D-Gal-induced acute liver failure in mice [J]. Journal of Practical Hepatology, 2020, 23(6): 781-784.
[14]	He Shengfu, Wang Yuqin. Role of bile acids in cholestatic liver injury [J]. Journal of Practical Hepatology, 2020, 23(6): 919-922.
[15]	Li Chen, Kan Jianying. Prediction of survival by donor’s serum cytokines in recipients of liver transplantation [J]. Journal of Practical Hepatology, 2020, 23(5): 739-742.